Reply: Olfaction and early detection of Parkinson's disease by Ponsen, M.M. et al.
VU Research Portal
Reply: Olfaction and early detection of Parkinson's disease




DOI (link to publisher)
10.1002/ana.20353
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Ponsen, M. M., Stoffers, D., Booij, J., Eck-Smit, B. L. F., Wolters, E. C. M. J., & Berendse, H. W. (2005). Reply:
Olfaction and early detection of Parkinson's disease. Annals of Neurology, 57(1), 157-158.
https://doi.org/10.1002/ana.20353
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 14. Sep. 2021
Olfaction and Early Detection of Parkinson’s
Disease
Erwin B. Montgomery, Jr, MD
The article by Ponsen and colleagues1 and the accompanying
editorial by Stern2 point out the importance of preclinical
detection of risk for subsequent development of Parkinson’s
disease. The interesting work by Ponsen and colleagues1
would suggest that tests of olfactory function, alone or in
combination with other tests, may play a role in developing
prognosticating tests. We developed such a test that, when
applied prospectively to 212 subjects with symptoms sugges-
tive but not diagnostic of Parkinson’s disease, was able to
detect 40 of the 59 subjects subsequently diagnosed with
Parkinson’s disease over a 2-year period.3,4 Also, the test bat-
tery, using tests of olfaction, motor speed, and depression,
was able to predict 37 of 40 subjects in whom Parkinson’s
disease subsequently was clinically excluded. The test battery
was 92% specific and 68% sensitive with an area of the re-
ceiver operator characteristics curve of 0.88. Olfactory testing
alone had a sensitivity of 82% and a specificity of 81%.
Developing any diagnostic or prognostic test is compli-
cated. In addition to specificity and sensitivity, prior proba-
bilities (prevalence of those at risk) are a major factor. For
example, the prevalence of persons at risk for Parkinson’s dis-
ease in a population of concern (such as first-degree relatives
or those with specific environmental exposures) would have
to be nearly 18% for olfactory testing to have a 50% positive
and negative predictive value. Even at this, there would be as
many false-positives and false-negatives as true-positives and
true-negatives. Often little attention is given to the antici-
pated prevalence rates of those at risk when discussing po-
tential diagnostic or predictive tests. Combining multiple
tests into a diagnostic or prognostic battery to improve spec-
ificity and sensitivity is problematic.3
Ultimately, the choice of diagnostic or predictive test is
social, that is, what are the social, economic, political, moral,
and ethical consequences of failing to treat someone at risk
versus treating someone not at risk. If an effective neuropro-
tective therapy is developed, who would be treated? What
would happen if an effective neuroprotective treatment cost
$10,000 per year and had to be taken continuously? Could
or would our society be willing to pay such a cost? Could or
would we say that only those who could afford neuroprotec-
tion are entitled to it? Perhaps it would be wise to devote
efforts to resolve these questions at the same time we are
developing neuroprotective therapies.
Department of Neurology, National Primate Research Center,
H6/538 CSC, University of Wisconsin, Madison, WI
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We are pleased with the interest in our study expressed by
Montgomery. He and his colleagues have developed a so-
called Parkinson’s disease (PD) test battery that includes a
single test of olfactory function, from a sample of controls
and PD patients in Hoehn and Yahr stages 2 and 2.5.1 The
test was applied subsequently to an independent sample of
individuals that is rather vaguely described as having “some
concern about the possibility of having PD,” “some problem
recorded on a questionnaire with high sensitivity and speci-
ficity for parkinsonism,” and “some symptoms referable to
PD.”2 This sample is referred to by Montgomery and col-
leagues as an enriched sample, chosen to increase the preva-
lence of participants that subsequently would develop clini-
cally diagnosable PD. However, this actually means that
participants were both subjectively and objectively showing
motor signs potentially indicative of PD. In contrast, the
population we studied to determine whether hyposmia
would antedate the development of clinical motor symptoms
in PD was both subjectively and objectively (United Parkin-
son’s Disease Rating Scale motor subscores 5) asymptom-
atic as far as motor signs of PD are concerned.3,4 Instead, we
chose to increase the prevalence of individuals that might
later develop PD by selecting first-degree relatives of PD pa-
tients (but not cases of familial forms of parkinsonism). In-
terestingly, Montgomery and colleagues actually applied the
PD test battery to a similar sample of asymptomatic first-
degree relatives of PD patients in an earlier study5 referred to
in our present and a previous publication.3,4 Although they
found an abnormal score on the PD test battery in 22.5% of
first-degree relatives (and in 9% of normal controls),
follow-up data so far have not been published. The results of
our ongoing prospective study constitute the first evidence
that unexplained olfactory dysfunction indeed can precede
motor impairments in PD and is associated with an in-
creased risk of PD subsequently developing in first-degree
relatives.4
We agree with Montgomery that the development of any
diagnostic test is fraught with difficulties. The same holds for
combining multiple tests into a diagnostic battery. Neverthe-
less, we should not refrain from trying. Considering that ol-
factory loss occurs in many other conditions, including Alz-
heimer’s disease, a combination with other tests may be
unavoidable when developing a screening test for PD. Al-
though our data suggest that adding single-photon emission
computed tomography (SPECT) scanning with a dopamine
transporter ligand would appear to be a promising approach,
we consider the number of individuals that would need to be
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scanned still too high for practical purposes. The first screen-
ing step before SPECT scanning probably should already in-
clude multiple modalities. This is what we are currently ex-
ploring the same cohort of first-degree relatives.
In the end, many factors come into play when considering
the actual implementation of a test battery for a neurodegen-
erative disorder. The first condition to fulfill is obviously the
development of an effective neuroprotective treatment strat-
egy. In balancing the costs of a neuroprotective treatment
against the benefits of this treatment, we should also consider
the current mean total annual costs of PD patients that are
as high as €13,800.6 At more advanced stages, when hospi-
talization becomes necessary, there is a substantial further in-
crease in costs up to an annual €29,000.7
1Research Institute Neurosciences Vrije Universiteit,
Department of Neurology, VU University Medical Center
Amsterdam; 2Department of Clinical Neuropsychology, Vrije
Universiteit; and 3Department of Nuclear Medicine, Academic
Medical Center, Amsterdam, The Netherlands
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Oligodendrocyte Apoptosis before Immune Attack
in Multiple Sclerosis?
Michael P. Pender, MD, PhD
Barnett and Prineas1 recently reported new morphological
findings in the brain of a 14-year-old patient with relapsing-
remitting multiple sclerosis (MS) who died within 24 hours
of the onset of a new symptomatic and fatal brainstem le-
sion. Within this early lesion, they observed extensive oligo-
dendrocyte cell death which they attributed to apoptosis.
Strikingly, no T lymphocytes were detected in the region of
oligodendrocyte death. In an accompanying editorial, Trapp2
suggests that this finding indicates that the immune response
in MS is not the cause of the oligodendrocyte cell death but
is secondary to oligodendrocyte death caused by an unknown
primary disease mechanism. Before accepting this interpreta-
tion, two points need to be considered. First, the patient
reported by Barnett and Prineas received an intravenous in-
jection of 100mg hydrocortisone.1 Corticosteroid administra-
tion reduces the number of T lymphocytes in the central
nervous system in rats with experimental autoimmune en-
cephalomyelitis (EAE).3 This commences as early as 4 hours
after subcutaneous corticosteroid administration.3 A dose of
0.25mg dexamethasone/kg (equivalent to 6.7mg hydrocorti-
sone/kg) inhibits the development of EAE by an effect on
lymphocyte migration rather than by inducing T-lymphocyte
apoptosis.4 Assuming a body weight of 50kg for the patient
reported by Barnett and Prineas, the dose of hydrocortisone
administered was 2mg/kg, which might have been sufficient
to clear T lymphocytes from the central nervous system after
these cells had induced oligodendrocyte death. Second, even
in the absence of T lymphocytes, antioligodendrocyte anti-
body can induce oligodendrocyte death and consequent de-
myelination in the absence of complement and macro-
phages.5 Such a mechanism also needs to be considered in
MS.
Neuroimmunology Research Centre, School of Medicine, The
University of Queensland, and Department of Neurology,
Royal Brisbane and Women’s Hospital, Brisbane, Queensland,
Australia
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Reply
John W. Prineas, MB, BS, and
Michael H. Barnett, MB, BS
Our study1 referred to by Professor Pender describes a very
early stage in the formation of new multiple sclerosis (MS)
lesions characterized by the presence of broad areas of palely
staining (but still largely intact) myelin sheaths, containing
apoptotic oligodendrocytes and activated microglia, but few
or no myelin phagocytes or lymphocytes. The absence of T
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lymphocytes in the immediate vicinity of apoptotic oligoden-
drocytes is especially significant, because such changes have
not been reported in any form of the animal model, exper-
imental allergic encephalomyelitis (EAE). As noted by our-
selves and Dr Trapp,2 this raises the possibility of important
differences in the pathogenesis of these two diseases. Profes-
sor Pender suggests that steroid administration shortly before
death may have cleared the central nervous system (CNS) of
T cells; this possibility can be ruled out first by the fact that
not all seven patients (in whom apoptotic lesions were iden-
tified) received such treatment, and second by the presence
of numerous lymphocytes in zones of active phagocytosis ad-
jacent to or contiguous with areas exhibiting prominent oli-
godendrocyte apoptosis in each of the 10 apoptotic lesions
described.
In the patient with the 17-hour symptomatic lesion, we
described an absence of lymphocytes in zones of oligoden-
drocyte apoptosis, but relatively numerous CD4, CD8, and
especially CD45RO T cells together with myelin phago-
cytes elsewhere in the lesion.1 Also as noted in our study, the
findings were consistent in each of the nine other apoptotic
lesions described.
Our findings argue strongly against direct T-cell–mediated
destruction of oligodendrocytes in early MS lesions. Rather,
they suggest that dissolution of myelin by macrophages is
largely or entirely scavenging activity directed against dead
myelin sheaths, that is, plasma membrane of apoptotic oli-
godendrocytes. As noted by Professor Pender, however, our
results do not rule out antibody or other humoral factors as
effectors of oligodendrocyte apoptosis in early MS lesions.
Department of Medicine, The University of Sydney, Sydney,
Australia
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